[1]闫文华,王颖,王先令,等.GnRH泵治疗卡尔曼综合征男性患者的有效性和安全性研究[J].国际内分泌代谢杂志,2021,41(06):591-595.[doi:10.3760/cma.j.cn121383-20200720-07050]
　Yan Wenhua,Wang Ying,Wang Xianling,et al.Efficacy and safety of GnRH pulsatile subcutaneous infusion in male patients with Kallmann syndrome[J].International Journal of Endocrinology and Metabolism,2021,41(06):591-595.[doi:10.3760/cma.j.cn121383-20200720-07050]
点击复制

GnRH泵治疗卡尔曼综合征男性患者的有效性和安全性研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
591-595
栏目:
论著
出版日期:
2021-12-20

文章信息/Info

Title:
Efficacy and safety of GnRH pulsatile subcutaneous infusion in male patients with Kallmann syndrome
作者:
闫文华1; 王颖2; 王先令1; 窦京涛1; 巴建明1; 吕朝晖1; 母义明1
1解放军总医院第一医学中心内分泌科,北京 100853; 2秦皇岛市海港医院内分泌科 066000
Author(s):
Yan Wenhua1;  Wang Ying2;  Wang Xianling1;  Dou Jingtao1;  Ba Jianming1;  Lyu Zhaohui1;  Mu Yiming1.
1Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China; 2Department of Endocrinology, Qinhuangdao Haigang Hospital, Qinhuangdao 066000, China
关键词:
促性腺激素释放激素(GnRH)泵;  戈那瑞林;  脉冲;  Kallmann综合征;  治疗
Keywords:
Gonadotropin releasing hormone(GnRH)pump;  Gonadorelin;  Pulse;  Kallmann syndrome;  Treatment
DOI:
10.3760/cma.j.cn121383-20200720-07050
摘要:
目的 通过观察促性腺激素释放激素(GnRH)泵皮下脉冲输注治疗男性卡尔曼综合征(Kallmann syndrome, KS)患者治疗前后的第二性征发育情况、激素水平变化及不良反应,探讨戈那瑞林皮下脉冲治疗的有效性和安全性。方法 纳入20例2012年3月至2019年6月解放军总医院第一医学中心确诊并自愿接受GnRH泵治疗的KS患者作为研究对象,观察治疗前、试戴期末(戴泵后第7天)、3个月、6个月及1年以上随访中促性腺激素、睾酮、睾丸超声、体征及自我体验的不同。结果 所有患者均进行了GnRH兴奋试验,60 min黄体生成素(LH)均值为(3.00±2.96)U/L。戴泵治疗1周时,LH[(12.30±11.95)U/L比(0.27±0.24)U/L,P<0.05]和卵泡刺激素[(4.99±2.84)U/L比(0.92±0.69)U/L,P<0.05]水平较基线水平显著升高。治疗半年和末次随诊时睾酮水平分别为(7.06±5.22)mmol/L和(9.78±8.10)mmol/L,均较基线水平[(1.46±1.40)mmol/L]显著升高(P均<0.01)。睾丸容积逐渐增大,治疗半年后,双侧睾丸容积之和(BTV)从(3.03±3.54)ml增加至(4.94±1.34)ml(P<0.05),末次随诊时,BTV达到(16.20±8.37)ml。所有患者的第二性征均有不同程度的改善,3例患者报告注射部位红肿不适,经对症处理后好转。结论 GnRH泵皮下脉冲输注戈那瑞林治疗KS患者安全有效。
Abstract:
Objective To investigate the efficacy and safety of subcutaneous pulse therapy with gonadorelin by observing the development of the secondary sexual character, hormone variations and adverse reactions in male patients with Kallmann syndrome(KS)before and after subcutaneous pulse infusion with gonadotropin releasing hormone(GnRH)pump.Methods 20 KS patients diagnosed and voluntarily treated with GnRH pump in the First Medical Center, Chinese PLA General Hospital between March 2012 and June 2019 were enrolled. The differences of gonadotropin, testosterone(T), testicular ultrasound, signs and self feeling were observed before treatment and 7 days, 3 months, 6 months and more than 1 year after treatment.Results GnRH stimulation test was carried out in all patients, and the mean value of 60 min luteinizing hormone(LH)was(3.00±2.96)U/L. The level of LH [(12.30±11.95)U/L vs.(0.27±0.24)U/L, P<0.05] and follicle-stimulating hormone(FSH)[(4.99±2.84)U/L vs.(0.92±0.69)U/L, P<0.05] were significantly higher than those of baseline after one week of pump wearing. T levels were(7.06±5.22)mmol/L and(9.78±8.10)mmol/L at half a year and the last follow-up, respectively, which were significantly higher than the baseline level [(1.46±1.40)mmol/L, all P<0.01]. The testicular volume increased gradually. Half a year after treatment, the bilateral testicular volume(BTV)increased from(3.03±3.54)ml to(4.94±1.34)ml(P<0.05). At the last follow-up, BTV rose to(16.20±8.37)ml. The secondary sexual character of all patients were improved to some extent. Three patients reported that the injection site was inflamed and uncomfortable, and relieved after symptomatic treatment.Conclusion Subcutaneous pulse infusion of gonadorelin with GnRH pump is safe and effective in the treatment of KS patients.

参考文献/References:

[1] Fraietta R,Zylberstejn DS,Esteves SC. Hypogonadotropic hypogonadism revisited[J].Clinics(Sao Paulo),2013,68(Suppl 1):81-88.DOI:10.6061/clinics/2013(sup01)09.
[2] 汪保安,马晓莉,邹效漫,等.女性特发性低促性腺激素性性腺功能减退症的临床评价及KAL1和FGFR1基因突变分析[J].解放军医学院学报,2011,32(10):1017-1019.DOI:11-3275/R.20110402.1454.001.
[3] 鄢春风,杨国庆,母义明,等.男性特发性低促性腺激素型性腺功能减退症87例临床分析[J].中国实用内科杂志,2007,27(23):1839-1841.DOI:10.3969/j.issn.1005-2194.2007.23.011.
[4] Sizonenko PC.Delayed puberty and hypogonadism//Wass JAH,Shalet SM.Oxford Textbook of Endocrinology and Diabetes[M].New York:Oxford Univereity Press Inc,2002:1035-1046.
[5] 李芳萍,程桦.男性特发性低促性腺激素性性功能减退症[J].国际内分泌代谢杂志,2007,27(6):370-372.DOI:10.3760/cma.j.issn.1673-4157.2007.06.003.
[6] Hoffman AR,Crowley WF Jr.Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone[J].N Engl J Med,1982,307(20):1237-1241.DOI:10.1056/NEJM198211113072003.
[7] Pitteloud N,Hayes FJ,Dwyer A,et al.Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism[J].J Clin Endocrinol Metab,2002,87(9):4128-4136.DOI:10.1210/jc.2002-020518.
[8] Koskenniemi JJ,Virtanen HE,Toppari J.Testicular growth and development in puberty[J].Curr Opin Endocrinol Diabetes Obes,2017,24(3):215-224.DOI:10.1097/MED.0000000000000339.
[9] 茅江峰,窦京涛,伍学焱.特发性低促性腺激素性性腺功能减退症诊治专家共识解读[J].中国实用内科杂志,2016,36(3):204-207.DOI:10.7504/nk2016020304.
[10] Gong C,Liu Y,Qin M,et al.Pulsatile GnRH is superior to hCG in therapeutic efficacy in adolescent boys with hypogonadotropic hypogonadodism[J].J Clin Endocrinol Metab,2015,100(7):2793-2799.DOI:10.1210/jc.2015-1343.

备注/Memo

备注/Memo:
通信作者:母义明,Email:muyiming@301hospital.com.cn
更新日期/Last Update: 2021-12-10